Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multicenter, Open-label, Randomized, Parallel-group, Multiple-dose Study to Assess the Effectiveness, Safety and Satisfaction With Collagenase Clostridium Histolyticum Grid Technique Injections of Buttock or Thigh Cellulite With Laxity in Adult Females

NCT04580303 is registered in ClinicalTrials.gov with Endo USA Inc., a Keenova Therapeutics Company as lead sponsor.

NCT NCT04580303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04580303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multicenter, Open-label, Randomized, Parallel-group, Multiple-dose Study to Assess the Effectiveness, Safety and Satisfaction With Collagenase Clostridium Histolyticum Grid Technique Injections of Buttock or Thigh Cellulite With Laxity in Adult Females
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2020
Completion date
September 24, 2021
Enrollment
35 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cellulite, edematous fibrosclerotic panniculopathy, laxity; skin